Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Brexafemme (Ibrexafungerp) is a first-in-class triterpenoid antifungal medication manufactured by Scynexis, Inc. and licensed to GSK for commercialization. It is FDA-approved for the treatment of vulvovaginal candidiasis (VVC) — commonly known as vaginal yeast infections — in adult and postmenarchal pediatric females. Brexafemme is also approved for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), making it the first oral non-azole treatment option for both acute and recurrent yeast infections.
Brexafemme works by inhibiting glucan synthase, an enzyme critical to forming 1,3-beta-D-glucan — an essential component of the fungal cell wall. By disrupting fungal cell wall formation, Brexafemme exhibits concentration-dependent fungicidal activity against Candida species. Unlike azole antifungals (like Fluconazole), Brexafemme targets a different pathway, which means it can be effective against azole-resistant and even echinocandin-resistant Candida strains, including C. auris.
Brexafemme has a findability score of 15 out of 100, making it extremely difficult to find in stock. Scynexis issued a voluntary nationwide recall in 2023 due to potential cross-contamination concerns, and the FDA placed a clinical hold that lasted approximately 19 months. While the clinical hold was lifted in May 2025, the product remains temporarily unavailable as Scynexis transfers the Brexafemme NDA to GSK. GSK plans regulatory discussions in 2026 to resume commercial availability, but there is no confirmed return date as of early 2026.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Brexafemme is most commonly prescribed by the following types of healthcare providers:
Telehealth consultations are also available for obtaining a Brexafemme prescription.
No, Brexafemme is not a controlled substance. It does not have a DEA schedule and does not carry a risk for abuse or dependence. However, it is a prescription-only medication and cannot be purchased over the counter.
Serious but less common side effects include hypersensitivity reactions, elevated liver enzymes (transaminases), dysmenorrhea, and vaginal bleeding. Brexafemme is contraindicated in pregnancy due to embryo-fetal toxicity observed in animal studies. Pregnancy must be verified before starting treatment, and effective contraception should be used during treatment and for 4 days after the last dose.
Brexafemme can be taken with or without food and has no significant food interactions. Weak and moderate CYP3A inhibitors do not require dose adjustments.
Brexafemme represents an important treatment option as the first oral non-azole antifungal for vulvovaginal candidiasis and recurrent VVC. However, due to the 2023 recall and subsequent FDA clinical hold, the medication remains temporarily unavailable in early 2026. GSK is working with the FDA to resume commercial availability, but no confirmed return date has been announced. Patients who need treatment for yeast infections should discuss alternatives like Fluconazole or OTC options with their healthcare provider. Use Medfinder to check availability as the situation evolves.
%2C%20Color%3DOriginal.png)
